ELAVL1 Promotes Proliferation and Inhibits Apoptosis of the Marek’s Disease Virus (MDV)-Transformed Cell Line MSB1 via the COX-2/PGE2 Pathway

Figures

• 

  Figure 1. Expression of ELAVL1 in MSB1 cells following transfection with pEGFP-C1-ELAVL1, pEGFP-C1, siELAVL1, or siNC. β-Actin was used as the control. Gene expression was normalized to the Control group. Each biological replicate was assayed in technical triplicate. Data are presented as mean ± SD from three independent biological replicates (n = 3). Comparisons between two groups were performed using a two-tailed Student’s t-test or Welch’s t-test when variances were unequal. ** p < 0.01 indicates a significant difference compared with the corresponding control group.

• 

  Figure 2. Cell viability of MSB1 cells after transfection with pEGFP-C1, pEGFP-C1-ELAVL1, siNC, or siELAVL1. Each biological replicate was assayed in technical triplicate. Data are presented as mean ± SD from three independent biological replicates (n = 3). Comparisons among multiple groups were performed using one-way ANOVA followed by Dunnett’s post hoc test to compare each treatment group with its corresponding control. (* p < 0.05, ** p < 0.01).

• 

  Figure 3. Flow cytometry analysis of the cell cycle in MSB1 cells following transfection with (A) pEGFP-C1; (B) pEGFP-C1-ELAVL1; (C) siNC; or (D) pEGFP-C1-siELAVL1; (E) Cell cycle distribution across experimental groups. G1: pre-DNA synthesis phase; S: DNA synthesis phase; G2: post-DNA synthesis phase. Data are presented as mean ± SD from three independent biological replicates (n = 3). Comparisons among multiple groups were performed using one-way ANOVA followed by Dunnett’s post hoc test to compare each treatment group with its corresponding control. (* p < 0.05, ** p < 0.01, ns, not significant).

• 

  Figure 4. Flow cytometric results for the apoptosis rate of MSB1 cells following modulation of ELAVL1 expression. Representative plots are shown for (A) pEGFP-C1 group, (B) pEGFP-C1-ELAVL1 group, (C) siNC group, and (D) pEGFP-C1-siELAVL1 group; (E) The proportion of apoptotic cells in the different experimental groups. Data are presented as mean ± SD from three independent biological replicates (n = 3). Comparisons between two groups were performed using a two-tailed Welch’s t-test. (** p < 0.01).

• 

  Figure 5. The effect of ELAVL1 on the expression of COX-2 and PGE2. (A,B) Relative mRNA levels of COX-2 and PGE2 in MSB1 cells transfected with pEGFP-C1-ELAVL1, pEGFP-C1-siELAVL1, or siNC, with β-actin as the loading control; (C) PGE2 concentration in cell culture supernatant, quantified using ELISA; (D) Representative Western blot images showing ELAVL1 and COX-2 protein levels; (E,F) Densitometric quantification of ELAVL1 and COX-2 protein levels normalized to β-actin. Each biological replicate was assayed in technical triplicate. Data are presented as mean ± SD from three independent biological replicates (n = 3). Comparisons between two groups were performed using a two-tailed Student’s t-test or Welch’s t-test when variances were unequal. (* p < 0.05, ** p < 0.01).